Clinical Data Abivax slides on phase 3 data in ulcerative colitis PharmaphorumShares in Abivax have tumbled after it announced phase 3 data with ulcerative colitis drug obefazimod that included several cases of cancer.Immunology & InflammationRead full story pharminent June 2, 2026 (Last updated: June 4, 2026) Pharmaphorum Shares in Abivax have tumbled after it announced phase 3 data with ulcerative colitis drug obefazimod that included several cases of cancer. Immunology & Inflammation Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Deep Science Ventures and MDC partner to accelerate brain treatmentsNext: AbiVax falls as safety worries cloud ‘landmark’ immune drug results Related Stories Clinical Data Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs pharminent July 14, 2026 Clinical Data Major trial launched to explore GLP-1 benefit in dementia pharminent July 13, 2026 Clinical Data GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China pharminent July 10, 2026
